Literature DB >> 29505718

Computer-Aided Formulation Design for a Highly Soluble Lutein-Cyclodextrin Multiple-Component Delivery System.

Qianqian Zhao1, Nikhila Miriyala2, Yan Su1, Weijie Chen1, Xuejiao Gao1, Ling Shao1, Ru Yan1, Haifeng Li3, Xiaojun Yao4, Dongsheng Cao5, Yitao Wang1, Defang Ouyang1.   

Abstract

Cyclodextrin (CD) complexation is widely used for the solubilization of poorly soluble drugs in the pharmaceutical industry. Current research was to develop a highly soluble lutein-cyclodextrin multiple-component delivery system (lutein-CD-MCDS) by combined modeling and experimental approaches. Both phase solubility diagram and molecular dynamics (MD) simulation results revealed that the interactions between lutein and CDs were very weak, which confirmed the insignificant solubility improvement of lutein-CD binary system. On the basis of theoretical calculation and preliminary CD studies, lutein-CD-MCDS was developed with over 400-fold solubility improvement after formulation screening. MD simulation indicated that the auxiliary polymers of TWEEN 80 and poloxamer 188 in the lutein-CD-MCDS introduced bridged interaction between lutein and γ-CD to increase the solubility, dissolution rate, and stability of the complex. The lutein-CD-MCDS was characterized by in vitro dissolution test, differential scanning colorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), and powder X-ray diffraction (PXRD). Moreover, lutein-CD-MCDS had significantly higher uptake in Caco-2 cells than free lutein. The relative bioavailability of the lutein-CD-MCDS increased to 6.6-fold compared to pure lutein, and to 1.2-fold compared with commercial lutein soft capsules. In conclusion, the highly soluble lutein-CD-MCDS with significant improvement in both the solubility and bioavailability was developed and characterized by combined modeling and experimental approaches. Our research indicates that computer-aided formulation design is a promising approach for future formulation development.

Entities:  

Keywords:  bioavailability; computer-aided formulation design; cyclodextrin; lutein; molecular dynamics simulation; multiple-component system

Mesh:

Substances:

Year:  2018        PMID: 29505718     DOI: 10.1021/acs.molpharmaceut.8b00056

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

1.  Investigation of molecular aggregation mechanism of glipizide/cyclodextrin complexation by combined experimental and molecular modeling approaches.

Authors:  Tianhe Huang; Qianqian Zhao; Yan Su; Defang Ouyang
Journal:  Asian J Pharm Sci       Date:  2018-12-08       Impact factor: 6.598

Review 2.  Mechanistic Understanding From Molecular Dynamics Simulation in Pharmaceutical Research 1: Drug Delivery.

Authors:  Alex Bunker; Tomasz Róg
Journal:  Front Mol Biosci       Date:  2020-11-25

3.  Integrated in silico formulation design of self-emulsifying drug delivery systems.

Authors:  Haoshi Gao; Haoyue Jia; Jie Dong; Xinggang Yang; Haifeng Li; Defang Ouyang
Journal:  Acta Pharm Sin B       Date:  2021-05-05       Impact factor: 11.413

4.  Prediction of small-molecule compound solubility in organic solvents by machine learning algorithms.

Authors:  Zhuyifan Ye; Defang Ouyang
Journal:  J Cheminform       Date:  2021-12-11       Impact factor: 5.514

5.  Predicting complexation performance between cyclodextrins and guest molecules by integrated machine learning and molecular modeling techniques.

Authors:  Qianqian Zhao; Zhuyifan Ye; Yan Su; Defang Ouyang
Journal:  Acta Pharm Sin B       Date:  2019-05-08       Impact factor: 11.413

6.  Solubility enhancement of mefenamic acid by inclusion complex with β-cyclodextrin: in silico modelling, formulation, characterisation, and in vitro studies.

Authors:  Dounia Sid; Milad Baitiche; Zineb Elbahri; Ferhat Djerboua; Mokhtar Boutahala; Zouhair Bouaziz; Marc Le Borgne
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.